Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Rilvegostomig · AZD-2936

Bispecific antibody · Antagonist of PD-1 (PDCD1) and TIGIT · developed by ASTRAZENECA

Phase 3 Most advanced trial

AZN Developer

1 Registered trials

What is Rilvegostomig?

Rilvegostomig is a bispecific antibody that binds and inhibits PD-1 and TIGIT, immune checkpoint proteins that suppress T-cell responses. By blocking these inhibitory signals, it restores T-cell activation and enhances immune responses against cancer cells. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD-2936
Drug type: Bispecific antibody
Targets: PD-1 (PDCD1), TIGIT, CD112 (NECTIN2) (binding partner it blocks), CD155 (PVR) (binding partner it blocks), CD226 (secondary target)
Mechanism: Antagonist of PD-1 (PDCD1) and TIGIT
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: YSL2GUT2Q8

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06868277	Phase 3	Carcinoma, Non-Small Cell Lung	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Non-Small Cell Lung

Other drugs acting on PDCD1 / TIGIT

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BMS-986442 Phase 1 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Rilvegostomig

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z